查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1630982

全球多种癌症早期检测市场：市场规模、份额和趋势分析（按类型、最终用途、地区和细分市场，2025-2030 年）

Multi Cancer Early Detection Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Gene Panel, LDT & Others), By End Use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

多种癌症早期检测 (MCED) 市场的成长和趋势：

根据Grand View Research, Inc.的最新报告，全球多种癌症早期检测市场规模预计到2030年将达到28.6亿美元，2025年至2030年复合年增长率为17%。

需要提供有效的癌症早期检测方法以便能够实施适当的治疗，以及癌症盛行率的上升和癌症类型的多样化，预计将推动市场成长。早期检测和诊断的需求有助于轻鬆管理疾病并降低后续死亡率，从而推动整个市场的发展。

多种癌症早期检测 (MCED) 测试旨在即使患者无症状时也能检测出体内的肿瘤。它会同时评估多种讯号来确定您是否可能患有癌症。目前已开发出多种检测方法用于早期发现癌症，但 MCED筛检测试是最近才在美国实用化的首个实验室开发的测试。例如，2022 年 7 月，GRAIL 的 Galleri 在圣路易斯的 Mercy 以 LDT 的形式开放。此外，Exact Sciences 和 Freenome 正在开发 MCED筛检测试，而 GRAIL 的 Galleri 测试无需保险即可推广，据称可以检测多达 50 种不同类型的测试。

研究表明，MCED 测试对于检测疾病的晚期或进展阶段比检测早期阶段更为敏感，而早期阶段是可以治疗，有时甚至可治癒的。此外，该测试具有高度特异性，这意味着没有癌症的人极不可能检测出阳性。目前，MCED 的开发研究仍在进行中，以满足早期诊断的需求。

市场上的领先公司声称他们可以识别从两三种到多达 50 种类型的癌症。公司专注于发展、开发和快速商业化这些筛检测试。例如，2020 年 12 月，Singlera Genomics 在 B 轮融资中筹集了 1.5 亿美元，用于开发、行销和推广其 MCED 测试。 GRAIL 与 Point32Health 启动了先导计画，使得 Point32Health 成为第一个包含 MCED 测试的商业健康计划。

多种癌症早期检测市场：分析概述

  • 基因组、LDT 和其他部分引领市场，到 2024 年将占据 91.28% 的份额。该领域的成长得益于 LDT 不需要 FDA核准即可在诊断实验室中使用。
  • 预计预测期内液态切片领域将以最快的复合年增长率成长。该细分市场的成长归因于越来越多的参与者获得投资者资金用于新测试开发。
  • 2024 年，医院终端用途领域占据市场主导地位，份额为 48.44%。这是因为人们越来越喜欢医院治疗，因为他们可以在一个地方获得一系列的服务。
  • 由于医疗保健基础设施的显着改善、人口的成长以及越来越多的当地企业进入市场，预计亚太地区多种癌症早期检测市场将在预测期内实现最快的复合年增长率。

目录

第一章 分析方法及范围

第 2 章执行摘要

3. 多种癌症早期检测 (MCED) 市场：驱动因素、趋势和范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 多种癌症早期检测 (MCED) 市场分析工具
    • 产业分析：波特五力分析
    • PESTEL 分析

第 4 章 多种癌症早期检测 (MCED) 市场：按类型进行估计和趋势分析

  • 按类型市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球多种癌症早期检测 (MCED) 市场展望（按类型）
  • 市场规模预测及趋势分析（2018-2030年）
  • 液态生物检体
  • 基因面板、LDT 等

5. 多种癌症早期检测 (MCED) 市场：按最终用途进行的估计和趋势分析

  • 按最终用途分類的市场占有率（2024 年和 2030 年）
  • 细分仪表板
  • 全球多种癌症早期检测 (MCED) 市场前景（按最终用途）
  • 市场规模预测及趋势分析（2018-2030年）
  • 医院
  • 诊断实验室
  • 其他的

6. 多种癌症早期检测 (MCED) 市场：区域估计和趋势分析

  • 各地区市场占有率（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 全球市场概况：按地区
  • 市场规模预测及趋势分析（2018-2030年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的近期趋势及影响分析
  • 公司/竞争对手分类
  • 供应商概况
    • 主要经销商及通路伙伴名单
    • Key customers
    • Key company market share analysis, 2024
    • Illumina, Inc. (GRAIL, LLC)
    • GRAIL, Inc.
    • Exact Sciences Corporation
    • FOUNDATION MEDICINE, INC.
    • AnchorDx
    • Guardant Health
    • Burning Rock Biotech Limited
    • GENECAST
    • Beijing Lyman Juntai International Medical Technology Development Co.
    • Freenome Holdings, Inc.
    • Elypta AB
Product Code: GVR-4-68039-966-1

Multi Cancer Early Detection Market Growth & Trends:

The global multi cancer early detection market size is expected to reach USD 2.86 billion by 2030, registering a CAGR of 17% from 2025 to 2030, according to a new report by Grand View Research, Inc. The need for providing effective ways to detect cancer at an early stage so that the right treatment can be given and the rising prevalence of cancer and multiple forms are expected to fuel the growth of the market. The requirement for early detection diagnostics, which facilitates simple disease management and subsequently lowers the death rate, drives the overall market.

Multi cancer early detection (MCED) tests are designed to find tumors in the body even when a patient is asymptomatic. To determine whether there is a high probability that a person has cancer, they simultaneously evaluate several signals. Although numerous tests are being developed to detect cancer at an early stage, the first MCED screening test was just recently made available in the U.S. as a lab-developed test. For instance, in July 2022, GRAIL's Galleri was made available as an LDT at Mercy, St. Louis. Furthermore, MCED screening tests are being developed by Exact Sciences and Freenome, and GRAIL's Galleri test is being marketed without payer coverage with the claim that it can detect up to fifty different forms.

Studies show that MCED tests have a higher sensitivity for detecting later-stage or advanced than for detecting earlier stages, which are more treatable and occasionally curable. Additionally, it was found that the tests were highly specific, which made it extremely unlikely that they would give a positive result for someone who did not have cancer. To meet the demand for early diagnosis, ongoing research is still being done in the field of developing MCED.

The major players in the market assert that they can identify as few as two or three different cancer types or as many as fifty. They are focusing on the growth and development of these screening tests and faster commercialization. For instance, in December 2020, Singlera Genomics raised $150 million in Series B funding for the development, marketing, and promotion of its MCED tests. GRAIL launched a pilot project with Point32Health, making Point32Health the first commercial plan for health to include MCED tests.

Multi Cancer Early Detection Market Report Highlights:

  • The gene panel, LDT, & others segment led the market and accounted for a share of 91.28% in 2024. The growth of the segment is attributed to the non-requirement of FDA approval for the utilization of LDT in diagnostic laboratories.
  • The liquid biopsy segment is anticipated to grow at the fastest CAGR over the forecast period. The growth of this segment is attributed to the increasing number of players receiving funding from investors for the development of new tests.
  • The hospitals end-use segment led the market with a share of 48.44% in 2024. This is attributed to the growing preference of hospitals for care due to the availability of various services under one roof.
  • Asia Pacific multi cancer early detection market is anticipated to witness the fastest CAGR over the forecast period due to a significantly improving healthcare infrastructure, a growing population, and a rising number of local companies entering the market

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Multi Cancer Early Detection (MCED) Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Extensive R&D for the development of MCED
      • 3.2.1.3. Need to develop diagnostic options that can detect cancer at an early stage
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Collection of adequate safety and efficacy data for regulatory approval
  • 3.3. Multi Cancer Early Detection (MCED) Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Multi Cancer Early Detection (MCED) Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Multi Cancer Early Detection (MCED) Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Liquid Biopsy
    • 4.5.1. Liquid biopsy market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Gene Panel, LDT, and Others
    • 4.6.1. Gene panel, LDT, and others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Multi Cancer Early Detection (MCED) Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Multi Cancer Early Detection (MCED) Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Hospitals
    • 5.5.1. Hospitals market estimates and forecasts 2018 - 2030 (USD million)
  • 5.6. Diagnostic Laboratories
    • 5.6.1. Diagnostic laboratories market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Other
    • 5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Multi Cancer Early Detection (MCED) Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. Illumina, Inc. (GRAIL, LLC)
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. GRAIL, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Exact Sciences Corporation
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. FOUNDATION MEDICINE, INC.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. AnchorDx
      • 7.3.8.1. Company overview
      • 7.3.8.2. Product benchmarking
      • 7.3.8.3. Strategic initiatives
    • 7.3.9. Guardant Health
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Burning Rock Biotech Limited
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. GENECAST
      • 7.3.11.1. Company overview
      • 7.3.11.2. Product benchmarking
      • 7.3.11.3. Strategic initiatives
    • 7.3.12. Beijing Lyman Juntai International Medical Technology Development Co.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Product benchmarking
      • 7.3.12.3. Strategic initiatives
    • 7.3.13. Freenome Holdings, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Product benchmarking
      • 7.3.13.3. Strategic initiatives
    • 7.3.14. Elypta AB
      • 7.3.14.1. Company overview
      • 7.3.14.2. Product benchmarking
      • 7.3.14.3. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America multi cancer early detection market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 6 U.S. multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 8 Canada multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 10 Mexico multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe multi cancer early detection market, by region, 2018 - 2030 (USD Million)
  • Table 12 Europe multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Germany multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 15 Germany multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 16 UK multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 17 UK multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 18 France multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 19 France multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Italy multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 21 Italy multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Spain multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 23 Spain multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Denmark multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 25 Denmark multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Sweden multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 27 Sweden multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 29 Norway multi cancer early detection market, by end use, 2018 - 2030 (USD Million)Asia Pacific multi cancer early detection market, by region, (USD Million) 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 31 China multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 32 China multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Japan multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 34 Japan multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 35 India multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 36 India multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 37 South Korea multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 38 South Korea multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Australia multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 40 Australia multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 42 Thailand multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America multi cancer early detection market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 45 Latin America multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 46 Brazil multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 47 Brazil multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Argentina multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 49 Argentina multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 50 MEA multi cancer early detection market, by region, 2018 - 2030 (USD Million)
  • Table 51 MEA multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 52 MEA multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 53 South Africa multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 54 South Africa multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 55 Saudi Arabia multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 57 UAE multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 58 UAE multi cancer early detection market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Kuwait multi cancer early detection market, by type, 2018 - 2030 (USD Million)
  • Table 60 Kuwait multi cancer early detection market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Multi cancer early detection market: market outlook
  • Fig. 14 Tumor ablation competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Multi cancer early detection market driver impact
  • Fig. 20 Multi cancer early detection market restraint impact
  • Fig. 21 Multi cancer early detection market strategic initiatives analysis
  • Fig. 22 Multi cancer early detection market: Type movement analysis
  • Fig. 23 Multi cancer early detection market: Type outlook and key takeaways
  • Fig. 24 Liquid biopsy market estimates and forecast, 2018 - 2030
  • Fig. 25 Gene panel, LDT, & others estimates and forecast, 2018 - 2030
  • Fig. 26 Multi cancer early detection market: End Use movement Analysis
  • Fig. 27 Multi cancer early detection market: End Use outlook and key takeaways
  • Fig. 28 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 29 Diagnostic laboratories market estimates and forecasts, 2018 - 2030
  • Fig. 30 Others market estimates and forecasts,2018 - 2030
  • Fig. 31 Global multi cancer early detection market: Regional movement analysis
  • Fig. 32 Global multi cancer early detection market: Regional outlook and key takeaways
  • Fig. 33 Global multi cancer early detection market share and leading players
  • Fig. 34 North America market share and leading players
  • Fig. 35 Europe market share and leading players
  • Fig. 36 Asia Pacific market share and leading players
  • Fig. 37 Latin America market share and leading players
  • Fig. 38 Middle East & Africa market share and leading players
  • Fig. 39 North America: SWOT
  • Fig. 40 Europe SWOT
  • Fig. 41 Asia Pacific SWOT
  • Fig. 42 Latin America SWOT
  • Fig. 43 MEA SWOT
  • Fig. 44 North America, by country
  • Fig. 45 North America
  • Fig. 46 North America market estimates and forecasts, 2018 - 2030
  • Fig. 47 U.S.
  • Fig. 48 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 49 Canada
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Mexico
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 53 Europe
  • Fig. 54 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 55 UK
  • Fig. 56 UK market estimates and forecasts, 2018 - 2030
  • Fig. 57 Germany
  • Fig. 58 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 59 France
  • Fig. 60 France market estimates and forecasts, 2018 - 2030
  • Fig. 61 Italy
  • Fig. 62 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 63 Spain
  • Fig. 64 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 65 Denmark
  • Fig. 66 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 67 Sweden
  • Fig. 68 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 69 Norway
  • Fig. 70 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 71 Asia Pacific
  • Fig. 72 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 73 China
  • Fig. 74 China market estimates and forecasts, 2018 - 2030
  • Fig. 75 Japan
  • Fig. 76 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 77 India
  • Fig. 78 India market estimates and forecasts, 2018 - 2030
  • Fig. 79 Thailand
  • Fig. 80 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 81 South Korea
  • Fig. 82 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 83 Australia
  • Fig. 84 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 85 Latin America
  • Fig. 86 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 87 Brazil
  • Fig. 88 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 89 Argentina
  • Fig. 90 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 91 Middle East and Africa
  • Fig. 92 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 93 South Africa
  • Fig. 94 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 95 Saudi Arabia
  • Fig. 96 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 97 UAE
  • Fig. 98 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 99 Kuwait
  • Fig. 100 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 101 Market share of key market players - Multi cancer early detection market